Activation of the complement system is important for efficient clearance of a wide variety of pathogens via opsonophagocytosis, or by direct lysis via complement-dependent cytotoxicity (CDC). However, in severe infections dysregulation of the complement system contributes to hyperinflammation. The influence of the novel IgM/IgA-enriched immunoglobulin preparation trimodulin on the complement pathway was investigated in in vitro opsonophagocytosis, binding and CDC assays. Immunoglobulin levels before and after trimodulin treatment were placed in relation to complement assessments in humans. In vitro, trimodulin activates complement and induces opsonophagocytosis, but also interacts with opsonins C3b, C4b and anaphylatoxin C5a in a concentration-dependent manner. This was not observed for standard intravenous IgG preparation (IVIg). Accordingly, trimodulin, but not IVIg, inhibited the downstream CDC pathway and target cell lysis. If applied at a similar concentration range in healthy subjects, trimodulin treatment resulted in C3 and C4 consumption in a concentration-dependent manner, which was extended in patients with severe community-acquired pneumonia. Complement consumption is found to be dependent on underlying immunoglobulin levels, particularly IgM, pinpointing their regulative function in humans. IgM/IgA provide a balancing effect on the complement system. Trimodulin may enhance phagocytosis and opsonophagocytosis in patients with severe infections and prevent excessive pathogen lysis and release of harmful anaphylatoxins.
17 April 2023 in International Journal of Blood Transfusion and Immunohematology
Aims: To assess potential changes of pharmacological activities of a novel normal immunoglobulin for intravenous administration from pooled normal plasma (IVIG). Methods: We assessed the impact of the SARS-CoV-2 pandemic on the level and activity of pathogen-specific antibodies in IVIG batches produced before and during the pandemic. Antibody levels were determined by immunoassays. The functional activity of SARS-CoV-2 antibodies was determined by in vitro neutralization. Results: In the IVIG, the antibody titer against bacteria, different viruses and a fungus were found to be in a defined range, whereas titers to common pathogens remained consistent over time, the level of antibodies to SARS-CoV-2 have increased within two years after onset of the pandemic to levels comparable to a hyperimmunoglobulin preparation. These antibodies could neutralize SARS-CoV-2 and cross-react with other coronaviruses. Conclusion: Increasing titers of SARS-CoV-2 antibodies might be beneficial for special vulnerable patient groups.